10 completed, 5 active not recruiting, 3 recruiting, 2 unknown. 13 Phase 2, 6 Phase 1, 2 Not applicable, 1 Phase 3.
Follow Peripheral blood: new trials by email Literature Review of Peripheral blood trials Research Report on Peripheral blood
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2022-12-29 | 2026-10-14 |
| S Protein and COVID-19: a Monocentric Prospective Study Hematolgy and Chemistry analysis, Real Time PCR, PROS assay COVID+ - COVID-19 | Unknown | University of Milano Bicocca | 70 | 2021-09-23 | 2024-01-02 | |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Biospecimen Collection, Carboplatin, Etoposide - Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma | Phase 2 | Recruiting | Children's Oncology Group | 160 | 2021-07-13 | 2026-09-23 |
| Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy AVB-S6-500, Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Withdrawn | Washington University School of Medicine | 2021-06-30 | 2021-09-29 | |
| A Study of N-acetylcysteine in Patients With COVID-19 Infection N-acetylcysteine, Peripheral Blood - Covid-19 | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2020-05-01 | 2026-05-01 |
| Palliative Lattice Stereotactic Body Radiotherapy (SBRT) Lattice stereotactic body radiation therapy, Peripheral blood - Cancer, Palliative Radiotherapy | Not applicable | Completed | Washington University School of Medicine | 20 | 2019-10-31 | 2021-11-22 |
| Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy Abemaciclib, Nivolumab, Tumor biopsy - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 6 | 2019-05-29 | 2020-12-03 |
| Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Bendamustine, Rituximab, Acalabrutinib - Mantle Cell Lymphoma | Phase 2 | Completed | Washington University School of Medicine | 13 | 2018-11-29 | 2026-04-21 |
| Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer PROSTVAC-V, PROSTVAC-F, Nivolumab - Metastatic Hormone-Sensitive Prostate Cancer | Phase 1 | Completed | Washington University School of Medicine | 19 | 2018-09-14 | 2022-08-05 |
| BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) BMS-813160, Nivolumab, Gemcitabine - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 40 | 2018-08-31 | 2025-07-29 |
| Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies peripheral blood - Leukemia | Unknown | National Taiwan University Hospital | 130 | 2018-03-09 | 2018-08-10 | |
| Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects Nasal lavage, Nasal allergen challenge, Epicutaneous skin testing - Nasal Allergy | Not applicable | Completed | Mitchell Grayson | 25 | 2017-09-06 | 2019-10-07 |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride - Plasma Cell Leukemia, Plasmacytoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 83 | 2015-09-14 | 2025-03-18 |
| Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy - Cancer of Head and Neck, Head and Neck Cancer | Phase 2 | Completed | Washington University School of Medicine | 67 | 2015-03-25 | 2026-08-05 |
| Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin - Ganglioneuroblastoma, Stage 1 Neuroblastoma | Phase 1 | Completed | Children's Oncology Group | 150 | 2013-04-09 | 2024-07-15 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Fludarabine phosphate, Busulfan, Total-Body Irradiation - Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 62 | 2012-12-24 | 2025-10-30 |
| Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease Blood samples - Acute Graft-versus-Host Disease, Allogeneic Stem Cell Transplant | Completed | Ohio State University Comprehensive Cancer Center | 259 | 2012-02-20 | 2025-01-20 |
Showing 20 of 22. Sign in to see all of them.
Leukemia, Myeloid, Acute (3) · Multiple Myeloma (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Aplastic (2) · COVID-19 (2) · Leukemia, Myelomonocytic, Chronic (2) · Primary Myelofibrosis (2) · Squamous Cell Carcinoma of Head and Neck (2) · Burkitt Lymphoma (1) · Carcinoma, Embryonal (1) · Carcinoma, Ovarian Epithelial (1) · Choriocarcinoma (1) · Fallopian Tube Neoplasms (1) · Ganglioneuroblastoma (1)
Washington University School of Medicine (7) · Children's Oncology Group (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Mitchell Grayson (1) · National Taiwan University Hospital (1) · Ohio State University Comprehensive Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Milano Bicocca (1)
United States (19) · Australia (2) · Canada (2) · New Zealand (2) · Italy (1) · Taiwan (1)
Douglas R Adkins, M.D. (2) · Monzr M Al Malki (2) · Brad S Kahl, M.D. (1) · Dolores Grosso, RN, CRNP, DNP (1) · Farhad Ravandi-Kashani (1) · Hannah Choe, MD (1) · Katherine C Fuh, M.D., Ph.D. (1) · Kian-Huat Lim, M.D., Ph.D. (1) · Lorenzo Iovino, MD, PhD (1) · Luisa Verga, MD (1) · Mary Meaghan P Granger (1) · Matthew Spraker, M.D., Ph.D. (1) · Mitchell H Grayson, MD (1) · Neal Flomenberg, MD (1) · Philip L McCarthy (1)
PMID 22571201, PMID 28826616, PMID 29618479, PMID 31491537, PMID 32665297, PMID 34195486
P30CA033572 (2), U10CA180886 (2), P50CA196510 (1), R01HL087778 (1), U10CA031946 (1), U10CA032102 (1), U10CA098543 (1), U10CA180821 (1), U10CA180888 (1)